Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C

Pierre Fenaux; Norbert Gattermann; John F. Seymour; Eva Hellstroem-Lindberg; Ghulam J. Mufti; Ulrich Duehrsen; Steven D. Gore; Fernando Ramos; Odile Beyne-Rauzy; Alan List; David McKenzie; Jay Backstrom; Charles L. Beach

doi:10.1111/j.1365-2141.2010.08082.x

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C

Pierre Fenaux, Norbert Gattermann, John F. Seymour, Eva Hellstroem-Lindberg, Ghulam J. Mufti, Ulrich Duehrsen, Steven D. Gore, Fernando Ramos, Odile Beyne-Rauzy, Alan List, David McKenzie, Jay Backstrom, Charles L. Beach

Research output: Contribution to journal › Article › peer-review

81 Citations (Scopus)

Abstract

P>In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with azacitidine. This analysis further compared the efficacy and the toxicity of these two drug regimens. Before randomization, investigators preselected patients to receive a conventional care regimen, one of which was LDara-C. Of 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and longer haematologicalal responses and increased red blood cell transfusion independence. Azacitidine prolonged overall survival versus LDara-C in patients with poor cytogenetic risk, presence of -7/del(7q), and French-American-British subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients.

Original language	English
Pages (from-to)	244 - 249
Number of pages	6
Journal	British Journal of Haematology
Volume	149
Issue number	2
DOIs	https://doi.org/10.1111/j.1365-2141.2010.08082.x
Publication status	Published - Apr 2010

Access to Document

10.1111/j.1365-2141.2010.08082.x

Cite this

Fenaux, P., Gattermann, N., Seymour, J. F., Hellstroem-Lindberg, E., Mufti, G. J., Duehrsen, U., Gore, S. D., Ramos, F., Beyne-Rauzy, O., List, A., McKenzie, D., Backstrom, J., & Beach, C. L. (2010). Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. British Journal of Haematology, 149(2), 244 - 249. https://doi.org/10.1111/j.1365-2141.2010.08082.x

@article{ddd8fe6df30942989e5216e3495f93b4,

title = "Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C",

abstract = "P>In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with azacitidine. This analysis further compared the efficacy and the toxicity of these two drug regimens. Before randomization, investigators preselected patients to receive a conventional care regimen, one of which was LDara-C. Of 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and longer haematologicalal responses and increased red blood cell transfusion independence. Azacitidine prolonged overall survival versus LDara-C in patients with poor cytogenetic risk, presence of -7/del(7q), and French-American-British subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients.",

author = "Pierre Fenaux and Norbert Gattermann and Seymour, {John F.} and Eva Hellstroem-Lindberg and Mufti, {Ghulam J.} and Ulrich Duehrsen and Gore, {Steven D.} and Fernando Ramos and Odile Beyne-Rauzy and Alan List and David McKenzie and Jay Backstrom and Beach, {Charles L.}",

year = "2010",

month = apr,

doi = "10.1111/j.1365-2141.2010.08082.x",

language = "English",

volume = "149",

pages = "244 -- 249",

journal = "British Journal of Haematology",

issn = "1365-2141",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

Fenaux, P, Gattermann, N, Seymour, JF, Hellstroem-Lindberg, E, Mufti, GJ, Duehrsen, U, Gore, SD, Ramos, F, Beyne-Rauzy, O, List, A, McKenzie, D, Backstrom, J & Beach, CL 2010, 'Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C', British Journal of Haematology, vol. 149, no. 2, pp. 244 - 249. https://doi.org/10.1111/j.1365-2141.2010.08082.x

TY - JOUR

T1 - Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C

AU - Fenaux, Pierre

AU - Gattermann, Norbert

AU - Seymour, John F.

AU - Hellstroem-Lindberg, Eva

AU - Mufti, Ghulam J.

AU - Duehrsen, Ulrich

AU - Gore, Steven D.

AU - Ramos, Fernando

AU - Beyne-Rauzy, Odile

AU - List, Alan

AU - McKenzie, David

AU - Backstrom, Jay

AU - Beach, Charles L.

PY - 2010/4

Y1 - 2010/4

N2 - P>In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with azacitidine. This analysis further compared the efficacy and the toxicity of these two drug regimens. Before randomization, investigators preselected patients to receive a conventional care regimen, one of which was LDara-C. Of 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and longer haematologicalal responses and increased red blood cell transfusion independence. Azacitidine prolonged overall survival versus LDara-C in patients with poor cytogenetic risk, presence of -7/del(7q), and French-American-British subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients.

AB - P>In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with azacitidine. This analysis further compared the efficacy and the toxicity of these two drug regimens. Before randomization, investigators preselected patients to receive a conventional care regimen, one of which was LDara-C. Of 94 patients preselected to LDara-C, 45 were randomized to azacitidine and 49 to LDara-C. Azacitidine patients had significantly more and longer haematologicalal responses and increased red blood cell transfusion independence. Azacitidine prolonged overall survival versus LDara-C in patients with poor cytogenetic risk, presence of -7/del(7q), and French-American-British subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year of drug exposure, azacitidine treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk MDS patients.

U2 - 10.1111/j.1365-2141.2010.08082.x

DO - 10.1111/j.1365-2141.2010.08082.x

M3 - Article

SN - 1365-2141

VL - 149

SP - 244

EP - 249

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C

Abstract

Access to Document

Fingerprint

Cite this